BPC-157 is generally well tolerated, but since its not approved as a drug, long-term human safety data is limited
In a pilot trial of NAD+ intravenous infusion in healthy adults, subjects receiving 750 mg of NAD+ over 6 hours reported no negative symptoms at all, and there were no vital sign abnormalities or serious laboratory derangements compared to placebo
Whether youre recovering from injury, managing inflammation, or want to support gut and joint health, BPC-157 could be the game-changer youve been waiting for .
Later, in the back of the cop car, you wonder: What exactly is blood alcohol level, and how is it accurately determined
However, long-term human safety data is still being established